Andrew Seidman, MD

Articles by Andrew Seidman, MD

Patients Prefer Subcutaneous Regimen for HER2-Positive Breast Cancer

January 6th 2022

Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma